EnteroBiotix lands $34m to take microbiome therapeutics into clinical trials

Company advances clinical-stage programs in IBS and liver disease using next-gen intestinal microbiota transfer technology.

Microbiome therapeutics company EnteroBiotix has successfully concluded a $34m funding round to support the advancement of clinical programs targeting multiple chronic conditions. The gut microbiome has long been implicated in healthy aging and longevity, helping regulate our immune system and reduce inflammation, both of which are involved in many age-related conditions. This presents potential avenues for microbiome-targeted interventions, and companies like EnteroBiotix are working to harness the power of the gut against a range of chronic diseases.

Based in Glasgow, Scotland, the clinical-stage biotech specializes in intestinal microbiota transfer (IMT), which describes the transfer of healthy microbiome communities into the intestinal tract of people suffering from microbiome-mediated disease. The technique is not new, but EnteroBiotix is targeting limitations in current practices, providing “standardised and compositionally consistent” solutions designed to restore and enhance gut microbial ecology via orally administered capsules containing colourless, odourless powder.

Photograph: EnteroBiotix

The new funding injection will fuel the progression of EnteroBiotix’s lead product candidate, EBX-102-02, through a Phase 2 clinical trial targeting Irritable Bowel Syndrome (IBS). In addition, it will advance the development of the company’s pipeline addressing other conditions associated with gut microbiome dysbiosis, including liver cirrhosis and hepatic encephalopathy, a condition describing changes in the brain that occur in patients with liver disease.

“This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome,” said Dr James McIlroy, CEO of EnteroBiotix It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market.”

The financing, consisting of new equity and the conversion of loan notes, was supported by a consortium of both new and existing investors, including Thairm Bio and Kineticos Life Sciences, alongside the Scottish National Investment Bank, Scottish Enterprise and others.

Photograph: EnteroBiotix